Administrative Digital SolutionsMedicare AdvantageJune 17, 2025

Specialty pharmacy precertification list expansion — key updates

Effective for dates of service on and after October 1, 2025, the specialty Medicare Part B drug listed in the table below will be included in our precertification review process.

Federal and state laws, along with state contract language and CMS guidelines — including definitions and specific contract provisions or exclusions — take priority over these precertification rules and must be considered first when determining coverage.

Note: Ensuring compliance with the new requirements will help facilitate claim approval.

HCPCS or CPT® codes

Medicare Part B drugs

J3590

Alhemo (concizumab‑mtci)

C9399, J9999

Datroway (datopotamab deruxtecan‑dlnk)

C9399, J9999

Grafapex (treosulfan)

C9399, J9999

Opdivo Qvantig (nivolumab hyaluronidase‑nvhy)

C9399, J3590

Steqeyma (ustekinumab‑stba)

C9399, J9999

Unloxcyt (cosibelimab‑ipdl)

J3590

Yesintek (ustekinumab‑kfce)

C9302

Ziihera (zanidatamab‑hrii)

Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CR-082709-25-CPN81629

PUBLICATIONS: July 2025 Provider Newsletter